Recombinant Signal recognition particle 54 kDa protein

What are the key structural domains of SRP54 and their functions?

SRP54 is a multi-domain protein consisting of an N-terminal domain, a GTPase (G) domain, and a methionine-rich M domain. The N and G domains (together referred to as NG domains) are responsible for GTP binding and hydrolysis, as well as interaction with the SRP receptor on the endoplasmic reticulum membrane. The C-terminal M domain binds to both SRP RNA and the signal sequences of nascent polypeptide chains at the polypeptide tunnel exit of the 60S ribosomal subunit . This domain organization is critical for the protein's function in the cotranslational targeting pathway .

How does SRP54 contribute to protein translocation?

SRP54 serves as the primary signal sequence recognition component of the signal recognition particle. During translation, SRP54 recognizes and binds to signal sequences of nascent polypeptide chains as they emerge from the ribosome. This initiates a series of events where SRP54, via its NG domains, binds to the SRP receptor on the ER membrane, facilitating the targeting of the ribosome-nascent chain complex to the ER. Upon successful targeting, SRP54 mediates the transfer of the signal peptide to the translocon, allowing the protein to be translocated into the ER for further processing and maturation . This process is essential for proper protein trafficking and secretion in eukaryotic cells.

What is the relationship between SRP54 and other SRP components?

In mammals, the SRP consists of a 300-nucleotide-long 7SL RNA and six polypeptides: SRP9, SRP14, SRP19, SRP54, SRP68, and SRP72 . Among these components, SRP54 and the SRP RNA are universally conserved across all phylogenetic groups, underscoring their essential roles. In the assembly of the human SRP, SRP54 associates with the larger domain of the SRP RNA, but only after SRP19 has bound to the RNA . SRP19 is believed to induce conformational changes in the RNA that allow SRP54 binding. Specifically, SRP54M (the M-domain) binds predominantly to helix 8 of the human SRP RNA, and this association is strictly dependent on protein SRP19 .

What expression systems are most effective for producing functional recombinant SRP54?

Recombinant human SRP54, containing the complete sequence (amino acids 1-504) with an expected molecular weight of 69.7 kDa, can be successfully expressed in Escherichia coli . For optimal expression, the SRP54 coding gene typically includes an N-terminal tag such as 6xHis-B2M, which facilitates detection and purification. When expressing full-length SRP54, researchers should be aware of potential aggregation issues due to hydrophobic interactions, particularly involving the M domain . To improve stability and reduce aggregation, truncated versions such as SRP54ΔC (with 70 residues deleted from the C-terminus) can be considered for certain applications. Alternative expression systems like insect cells might be beneficial for producing properly folded mammalian SRP54, especially when post-translational modifications may be important for the specific research application.

How can one assess the functional integrity of purified recombinant SRP54?

The functional integrity of recombinant SRP54 can be assessed through multiple assays:

• GTPase activity assay: Using a malachite green assay to measure phosphate release during GTP hydrolysis. Functional SRP54 should exhibit GTPase activity, which is crucial for its role in protein targeting .

• Ribosome binding assay: Microscale thermophoresis (MST) can be used to measure the affinity of SRP54 for ribosomes. Full-length SRP54 typically exhibits high-affinity binding with KD values in the nanomolar range (approximately 30 ± 10 nM) .

• SRP RNA binding assay: Electrophoretic mobility shift assays (EMSA) can determine whether recombinant SRP54M properly binds to SRP RNA, specifically to helix 8 as observed in native complexes .

• Signal sequence binding: Using synthetic signal sequences or fusion constructs with typical signal sequences to assess the ability of the M domain to recognize and bind these sequences .

How can one reconstitute a functional SRP system in vitro for mechanistic studies?

Reconstituting a functional human SRP system in vitro requires careful assembly of all components. First, SRP RNA (either SRPS RNA or complete 7SL RNA) must be properly folded. For SRPS RNA, snap-cooling is effective, while for complete 7SL RNA, slow-cooling yields better results . Next, SRP proteins should be added in a specific order: SRP19 should be added first to induce conformational changes in the RNA, followed by SRP54, and then other SRP proteins. The completed complex can be purified using appropriate chromatography techniques.

For studying the complete targeting system, researchers can further incorporate the SRP receptor (SR) and ribosomes or ribosome-nascent chain complexes (RNCs). MST analysis has shown that complete recombinant SRP/SR systems bind to RNCs exposing an SRP-targeting signal with very high affinity (KD < 0.9 nM) . This reconstituted system allows for detailed mechanistic studies of protein targeting and the roles of individual components.

What approaches can be used to study the dynamics of SRP54-ribosome interactions?

Understanding the dynamics of SRP54-ribosome interactions requires specialized techniques:

• Microscale thermophoresis (MST): This technique can measure binding affinities under equilibrium conditions. Studies have shown that SRP54 alone binds to ribosomes with high affinity (KD of ~30 nM), while the complete SRP exhibits even stronger binding (KD < 4.7 nM) .

• Cryo-electron microscopy (cryo-EM): This can provide structural insights into the SRP54-ribosome complex at different stages of the targeting process.

• Fluorescence resonance energy transfer (FRET): By labeling specific domains of SRP54 and the ribosome, researchers can monitor conformational changes during complex formation and dissociation.

• Single-molecule techniques: These can reveal the kinetics and heterogeneity of SRP54-ribosome interactions that might be masked in bulk measurements.

• Domain-specific studies: Separating the contributions of different SRP54 domains (NG and M) reveals a bimodal binding mode, with the M domain showing higher affinity (KD ~100 nM) compared to the NG domain (KD ~1.65 μM) .

How do mutations in the GTPase domain affect SRP54 function?

Mutations in the GTPase domain of SRP54 can significantly impair its function, with both structural and clinical implications. Three specific mutations—p.T115A, p.T117del, and p.G226E—located in highly conserved regions of the G domain have been shown to affect GTP and receptor binding . These mutations disrupt the GTPase activity of SRP54 to varying degrees:

• p.G226E mutation: Reduces GTPase activity by a factor of 3.5 and is predicted to affect receptor binding by creating extremely short contacts between E226 in SRP54 and G233, T232, and D43 in the receptor .

• p.T115A mutation: Almost completely abolishes phosphate release, indicating severe impairment of GTPase function .

• p.T117del mutation: Shows a moderate 1.6-fold decrease in enzymatic activity .

These mutations have been linked to syndromic neutropenia with Shwachman-Diamond Syndrome-like features, highlighting the critical importance of proper SRP54 function in cellular homeostasis. Researchers studying these mutations can employ site-directed mutagenesis to introduce them into recombinant SRP54 for functional studies.

How can one experimentally demonstrate SRP54's signal sequence recognition capability?

To experimentally demonstrate SRP54's signal sequence recognition capability, researchers can employ several approaches:

• Signal sequence fusion constructs: A typical signal sequence (e.g., from yeast dipeptidyl aminopeptidase B) can be fused to the C-terminus of full-length SRP54 (creating SRP54ss). This approach has been validated for studying the pre-handover state of SRP-RNC interactions .

• Crosslinking assays: Chemical crosslinking followed by mass spectrometry can identify specific residues in the M domain that interact with signal sequences.

• Binding affinity measurements: MST or other binding assays can compare the affinities of SRP54 for ribosomes with and without exposed signal sequences. SRP incorporating SRP54ss has been shown to bind ribosomes with very strong affinity (KD < 2.0 nM) .

• Mutational analysis: Systematically mutating residues in the M domain, particularly methionine residues thought to form a hydrophobic binding pocket, can identify key amino acids involved in signal sequence recognition.

• Competition assays: Using synthetic signal peptides to compete with RNCs for binding to SRP54 can provide insights into the specificity and affinity of signal sequence recognition.

What is the structural basis for the flexibility of SRP54 in scanning for signal sequences?

The flexibility of SRP54, crucial for scanning nascent polypeptide chains for signal sequences, is structurally facilitated by:

• Domain organization: X-ray crystallography studies reveal that SRP54 adopts an extended conformation, but the relative orientation of the linker and M domain can vary significantly between different structures .

• Pivot points: The flexibility is enabled by conserved glycine residues that act as pivot points. These residues are part of a conserved motif R292XLG295XG297D298 (using Pfu sequence numbering), located between helix α7 at the C-terminal part of the G domain and the linker .

• Linker region: The length and flexibility of the linker connecting the NG and M domains allow the M domain to sample diverse conformations while scanning for signal sequences emerging from the ribosomal exit tunnel .

• Conformational adaptation: The affinity of SRP for presecretory proteins depends on nascent chain length, which is likely related to the flexibility and length of the linker enabling SRP to adapt its conformation to different nascent chains .

This structural flexibility explains how SRP54 can efficiently recognize diverse signal sequences and adapt to different stages of translation, a critical aspect of its function in cotranslational protein targeting.

What are the implications of SRP54 mutations in human disease?

Mutations in the SRP54 gene have significant clinical implications, particularly in the context of congenital neutropenia and related disorders:

• Syndromic neutropenia: De novo missense variants in SRP54 have been identified in patients with syndromic neutropenia resembling Shwachman-Diamond Syndrome (SDS) . These patients exhibit congenital neutropenia along with various other SDS-like phenotypes.

• Molecular mechanisms: The disease-causing mutations (p.T115A, p.T117del, and p.G226E) affect highly conserved amino acids within the GTPase domain that are critical for GTP and receptor binding . These mutations impair the GTPase activity of SRP54, disrupting its function in protein targeting.

• Expression effects: SRP54 mRNA levels in bone marrow from patients with SRP54 mutations are approximately 3.6-fold lower than in healthy controls , suggesting that the mutations may affect expression or stability of the transcript.

• Phenotypic manifestations: Patients with SRP54 mutations show profound reductions in neutrophil counts and chemotaxis, as well as a diminished exocrine pancreas size , consistent with the role of SRP54 in cellular protein trafficking and secretion.

These findings highlight the essential role of SRP54 in normal cellular function and development, particularly in hematopoietic and exocrine pancreatic tissues.

How can recombinant SRP54 be used in translational research approaches?

Recombinant SRP54 offers several opportunities for translational research:

• Drug discovery: Recombinant SRP54 can be used in high-throughput screening assays to identify compounds that might modulate its activity, potentially leading to therapeutics for SRP54-related disorders.

• Functional assays for variant classification: Recombinant SRP54 variants can be produced to functionally characterize variants of uncertain significance identified in patients, helping to establish their pathogenicity.

• Biomarker development: Antibodies against recombinant SRP54 can be developed for immunoassays to measure SRP54 levels in patient samples, potentially serving as biomarkers for disease progression or treatment response.

• Gene therapy approaches: Understanding the structure-function relationships of SRP54 through recombinant protein studies can inform gene therapy approaches for SRP54-related disorders.

• Protein replacement strategies: For severe loss-of-function mutations, recombinant SRP54 production methodologies could potentially be adapted for therapeutic protein production, though delivery to appropriate cellular compartments remains challenging.

These translational applications underscore the importance of basic research on recombinant SRP54 for advancing our understanding and treatment of related human diseases.